For 2022, we have two products under review by FDA, both are licensed products co-developed with partners. We expect approval for one during the first half of 2022.
from Seeking, Elite transcript, looks like they filed 2 products, last year, and since it was done by a 2nd or 3rd party Elite didn't have to file 8Ks, now there is 3 month's left in the first half.
there is more:
Currently, Elite is working on number of generic ANDAs. The products include, those that were mentioned before, such as the central nervous system product and co-development antibiotic tablet.
Concerta has been rumored, but not sure, CNS to be named later.
